NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 2Nd September, 2022
Outcome of the Board Meeting held on 2nd September, 202202-09-2022
02-09-2022
Natco Pharma scouting for buys to boost domestic biz
Natco Pharma The Hyderabad-based company is interested in an entity with a revenue of 100 to 200 crore18-08-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings Call Transcript for the Q1 FY22-2317-08-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO announces tentative approval to its ANDA for Trabectedin (generic for Yondelis(r))17-08-2022
Hold Natco Pharma: target of Rs 735: ICICI Direct
ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 735 in its research report dated August 13, 2022.16-08-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Natco Pharma Limited has informed the Exchange about Newspaper Advertisements for Intimation of Record Date12-08-2022
Results Earnings Call for Q1FY23 of Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.11-08-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
weblink for the Audio Transcript for the Earnings call held on 10th August, 202210-08-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter ended 30th June, 202210-08-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication for unaudited financial results for the quarter ended 30th June, 202210-08-2022